Oxford Immunotec Global PLC (NASDAQ: OXFD), a global commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Stephen M. Gansler has joined the Company as Senior Vice President and Global Head of Human Resources. Mr. Gansler brings to Oxford Immunotec more than 25 years of experience in managing and leading the human resource function at life sciences companies. Most recently, Mr. Gansler was Senior Vice President, Human Resources, for Millennium Pharmaceuticals, where he played a key leadership role in the company’s growth. During his tenure with Millennium, it was consistently ranked as one of the best places to work in the United States. Before joining Millennium, Mr. Gansler spent more than 20 years with Johnson & Johnson, holding a variety of roles of increasing responsibility, including the head of human resources for four separate business units, and successfully leading several post-acquisition integrations.

“Oxford Immunotec is a fast growing leader in the field of immunology-based diagnostics and I am excited about the opportunity to play a role in its continued growth and success,” said Mr. Gansler.

“Steve brings a wealth of human resource management knowledge, leadership and general management expertise to Oxford Immunotec,” said CEO, Dr. Peter Wrighton-Smith. “We are very pleased to have him join our team and look forward to his significant contribution to our continued growth and success.”

Mr. Gansler received his Bachelor Industrial Administration from the General Motors Institute and a Master of Business Administration-Finance and Juris Doctor from Seton Hall University.

About Oxford Immunotec   

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company’s initial product is the T-SPOT®.TB test, which is used to test for latent tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company has seven active development programs, each of which leverages our T cell and innate immune measuring technology. The two most advanced products are focused on the transplantation market. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.